ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors
2024年5月13日 - 8:30PM
ビジネスワイヤ(英語)
ReCode Therapeutics, a clinical-stage genetic medicines company
using tissue-specific delivery to power the next wave of mRNA and
gene correction therapeutics, today announced the appointment of
Dean J. Mitchell as chairman of its Board of Directors. Mr.
Mitchell is a highly experienced and well-regarded biotechnology
and pharmaceutical industry veteran who brings over three decades
of experience as a board director and corporate executive to the
ReCode board.
“We are delighted to have Dean join the board as we continue to
advance our respiratory clinical development programs and leverage
our novel SORT LNP delivery platform to expand our portfolio,” said
Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of
ReCode Therapeutics. “His proven track record at growing and
scaling biopharma companies is a welcome addition to our board that
will support the company’s near- and long-term growth.”
“I am pleased to join the talented ReCode board at a pivotal
time for the company as it continues to achieve significant
milestones for its lead clinical programs and expand its research
and discovery efforts into gene correction,” said Mr. Mitchell. “I
look forward to working with the board and the executive team to
advance these novel therapies with the goal of one day providing
much-needed treatments for patients living with rare diseases.”
Mr. Mitchell currently serves as chairman of the Board of
Directors of Praxis Precision Medicines, Inc., an appointment he
has held since 2020, and as a board director for Theravance
Biopharma, Inc. (since 2014) and Precigen (since 2009). Mr.
Mitchell previously served as board chairman of Kinnate Biopharma,
Inc. until its sale in 2024 and as board director for ImmunoGen,
Inc. until its sale in 2024. He served as executive board chairman
for Covis Pharma Holdings until its sale in 2020 and board chairman
of PaxVax Corporation until its sale in 2018.
Mr. Mitchell previously held the position of president and chief
executive officer at Lux Biosciences, Inc., a biotechnology company
focusing on the treatment of ophthalmic diseases, at Alpharma,
Inc., a publicly traded specialty pharmaceutical company until its
acquisition by King Pharmaceuticals, Inc., and at Guilford
Pharmaceuticals, Inc., a publicly traded pharmaceutical company
focused on oncology and acute care, until its acquisition by MGI
Pharma Inc. He previously held executive roles at Bristol Myers
Squibb and GlaxoSmithKline. Mr. Mitchell earned a B.A. from City
University London and a B.Sc. in biology from Coventry
University.
About ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines
company using precision delivery to power the next wave of mRNA and
gene correction therapeutics. ReCode’s proprietary Selective Organ
Targeting (SORT) lipid nanoparticle (LNP) platform enables highly
precise and targeted delivery of genetic medicines directly to the
organs, tissues, and cells implicated in disease, enabling improved
efficacy and potency. ReCode’s lead programs include RCT1100 for
the treatment of primary ciliary dyskinesia caused by pathogenic
mutations in the DNAI1 gene, and RCT2100 for the treatment of the
10-13% of cystic fibrosis patients who have Class I mutations in
the CFTR gene and do not respond to currently approved CFTR
modulators. RCT1100 and RCT2100 are inhaled disease-modifying
mRNA-based therapies formulated using the SORT LNP delivery
platform. ReCode is expanding its pipeline to develop potential
therapies for other rare and common genetic diseases, including
musculoskeletal, central nervous system, liver, and infectious
disease indications.
ReCode has been recognized by the San Francisco Business Times
and Silicon Valley Business Journal as a Best Place to Work. For
more information, visit www.recodetx.com and follow us on LinkedIn
and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513239507/en/
Investor Contact: Anne Marie
Fields Stern IR annemarie.fields@sternir.com IR@recodetx.com
Media Contacts: Erica
Jefferson SVP, Corporate Affairs ReCode Therapeutics
ejefferson@recodetx.com 650-629-7965
Tara Cooper The Grace Group tara@gracegroup.us 650-303-7306